Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 8, 1998, Pages 2830-2835

  Park, Kyong Soo ^a,b   Ciaraldi, Theodore P ^a,b   Lindgren, Kristin ^a,b   Abrams Carter, Leslie ^a,b   Mudaliar, Sunder ^a,b   Nikoulina, Svetlana E ^a,b   Tufari, Sherrie R ^c   Veerkamp, Jacques H ^d   Vidal Puig, Antonio ^e   Henry, Robert R ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c PFIZER INC   (United States)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID BINDING PROTEIN; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GLUCOSE METABOLISM; HORMONE SENSITIVITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SKELETAL MUSCLE;

ADULT; CARRIER PROTEINS; CELLS, CULTURED; CHROMANS; DIABETES MELLITUS, TYPE 2; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; MUSCLE, SKELETAL; MYELIN P2 PROTEIN; NEOPLASM PROTEINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0001102396     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.8.2830     Document Type: Article

References (32)

1. Baron, AD, Laasko M, Brechtel G, Edelman SV. 1991 Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in non-insulin dependent diabetic subjects. J Clin Invest. 87:1186-1194.
2. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. 1988 Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1549-1558.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA. 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPARy). J Biol Chem. 270:12953-12956.
4. Schoonjans K, Staels B, Auwerx J. 1996 The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1302:93-109.
5. Braissant O, Foufelle F, Scotto C, Cauca M, Wahli W. 1996 Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -B, and -γ in the adult rat. Endocrinology. 137:354-366.
6. Jones PS, Savory R, Barratt F, et al. 1995 Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. Eur J Biochem. 233:291-226.
7. Fajas L, Aubeouf D, Raspe E, et al. 1997 The organization, promoter analysis, and expression of the human PPAR-γ gene. J Biol Chem. 272:18779-18789.
8. Elbrecht A, Chen Y, Cullinan CA, et al. 1996 Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun. 224:431-437:1996.
9. Shoonjans K, Staels B, Auwerx J. 1996 Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37:907-925.
10. Hu E, Tontonoz P, Spiegelman BM. 1995 Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc Natl Acad Sci USA. 92:9856-9860.
11. Willson TM, Cobb JE, Cowan DJ, et al. 1996 The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidenediones. J Med Chem. 39:665-668.
12. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. 1997 Peroxisome proliferator-activated receptor gene expression in human tissues effects of obesity, weight loss, and regulation by insulin and glucocoritcoids. J Clin Invest. 99:2416-2422.
13. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. 1997 PPARγ gene expression is elevated in skeletal muscle of obese and Type II diabetic subjects. Diabetes. 46:1230-1234.
14. Henry RR, Abrams E, Nikoulina S, Ciaraldi TP. 1995 Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes. 44:936-946.
15. Park K, Ciaradli TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. 1998 Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type 2 diabetic subjects. J Clin Endocrinol Metab 83:1636-1643.
16. National Diabetes Data Group. 1979 Classification, and diagnosis of diabetes mellitus and other categories of glucose tolerance. Diabetes. 28:1039-1057.
17. Vidal-Puig A, Jimenez-Linan M, Lowell BB, et al. 1996 Regulation of PPAR γ gene expression by nutrition and obesity in rodents. J Clin Invest. 97:2553-2561.
18. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB. 1997 UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun. 235:79-82.
19. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE. 1996 Glycogen synthase activity is reduced in cultured skeletal muscle cells of NIDDM subjects: biochemical and molecular mechanisms. J Clin Invest. 98:1231-1236.
20. Camp HS, Tafuri SR. 1997 Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen activated kinase. J Biol Chem. 272:10811-10816.
21. Saltiel AR, Olefsky JM. 1996 Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661-1669.
22. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky J. 1992 Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
23. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with trogli-tazone. N Engl J Med. 331:1188-1193.
24. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM. 1995 Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 44:976-982.
25. Tafuri SR. 1996 Troglitazone enhances differentiation, basal glucose uptake, and GLUT1 protein levels in 3T3-L1 adipocytes. Endocrinology. 137:4706-4712.
26. Kellerer M, Kroder G, Tippmer S, et al. 1994 Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes. 43:447-453.
27. Sandouk T, Rada D, Hofmann C. 1993 The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrionolgy. 133:352-359.
28. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM. 1995 PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol. 15:351-357.
29. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. 1994 The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA. 91:11012-11016.
30. Veerkamp JH. 1995 Fatty acid transport and fatty acid-binding proteins. Proc. Nutr Soc. 54:23-37.
31. Teboul L, Gaillard D, Staccini L, Inadera H, Amri E-Z, Grimaldi PA. 1995 Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J Biol Chem. 270:28183-28187.
32. Spiegelman BM, Flier JS. 1996 Adipogenesis and obesity: rounding out the big picture. Cell. 87:377-389.